Publications

Export 1328 results:
Sort by: Author Title [ Type  (Desc)] Year
Journal Article
Abd El Rahman, M. Y., H. Abdul-Khaliq, M. Vogel, V. Alexi-Meskischvili, M. Gutberlet, R. Hetzer, and P. E. Lange, "Value of the new Doppler-derived myocardial performance index for the evaluation of right and left ventricular function following repair of tetralogy of fallot.", Pediatric cardiology, vol. 23, issue 5, pp. 502-7, 2002 Sep-Oct. Abstract

The systolic and diastolic function in both ventricles may be altered even after successful corrective surgery of tetralogy of Fallot. The aim of this study was to assess the combined diastolic and systolic function of both ventricles using the Doppler-derived myocardial performance index (MPI) in patients with operated tetralogy of Fallot (TOF). We performed a prospective analysis of 51 patients following corrective surgery of TOF: 21 had a subannular patch, 20 had a homograft implantation at initial operation, and 10 were reoperated with secondary homograft implantation. Patients were examined with Doppler echocardiography, and the MPI, which incorporates ejection and isovolumetric relaxation and contraction times and is an index of global ventricular function, was calculated 10.2 +/- 8.0 (0.89-36) years after surgery. In 86.4% of the examined patients the right ventricular isovolumetric relaxation time was shortened compared to the normal published range or even did not exist (negative value) (p <0.01). The right ventricular MPI was paradoxically below the normal published range in 76.5% of the examined patients. The left ventricle global function was impaired in 23.5% of the examined patients, mainly due to altered systolic function with a prolonged left ventricular isovolumetric contraction time. The z score of the comparison between patients' left ventricular isovolumetric contraction time and the normal published values was 3.03. Patients with severe pulmonary regurgitation also had a prolongation of the isovolumetric relaxation time compared to patients with mild to moderate pulmonary regurgitation. The noncompliant right ventricle may shorten the right ventricular isovolumetric relaxation time, resulting in a paradoxically low right MPI. This may reduce the sensitivity of the index in recognizing patients with right ventricular dysfunction following corrective surgery of TOF. Additional diastolic impairment occurs in patients with right ventricular volume overload.

Rimoin, A. W., C. F. L. Walker, R. A. Chitale, H. S. Hamza, A. Vince, D. Gardovska, A. L. da Cunha, S. Qazi, and M. C. Steinhoff, "Variation in clinical presentation of childhood group A streptococcal pharyngitis in four countries.", Journal of tropical pediatrics, vol. 54, issue 5, pp. 308-12, 2008 Oct. Abstract

We conducted a cross-sectional study from September 2001 to August 2003 during which children between 2 and 12 years of age presenting with complaint of sore throat were recruited from urban pediatric clinics in Brazil, Croatia, Egypt and Latvia. The objective of the study was to compare clinical signs and symptoms of children presenting to urban pediatric clinics with sore throat in and between countries and to identify common clinical criteria predicting group A beta hemolytic streptococcal (GAS) pharyngitis. Using a single standard protocol in all four sites, clinical data were recorded and throat swabs obtained for standard GAS culture in 2040 children. Signs and symptoms were tested for statistical association with GAS positive/negative pharyngitis, and were compared using chi(2) tests, ANOVA and Odds Ratios. Clinical signs of GAS pharyngitis in children presenting to clinics varied significantly between countries, and there were few signs or symptom that could statistically be associated with GAS pharyngitis in all four countries, though several were useful in two or three countries. Our results indicate that the clinical manifestations of pharyngitis in clinics may vary by region. It is therefore critical that clinical decision rules for management of pharyngitis should have local validation.

Adly, A. A., D. Davino, A. Giustiniani, and C. Visone, "Vector magnetic hysteresis modeling of stress annealed galfenol", Journal of Applied Physics, vol. 113, no. 17: AIP Publishing, pp. 17A931, 2013. Abstract
n/a
Ertekin, E., I. M. van Hagen, A. M. Salam, R. Titia P.E, M. R. Johnson, J. Popelova, W. A. Parsonage, Z. Ashour, A. Shotan, J. M. Oliver, et al., "Ventricular tachyarrhythmia during pregnancy in women with heart disease, Data from ROPAC, a registry from the European Society of Cardiology", Int. J. Cardiol, vol. Oct, issue 220, pp. 131-136, 2016.
Elbendary, A., M. Valdebran, and R. Xue, "Violaceous Papules Presenting on the Foot and Lower Limb: Challenge.", The American Journal of dermatopathology, 2018 Dec 19.
Fisher, B. J., D. Kraskauskas, B. Mohammed, E. J. Martin, D. Brophy, N. F. Voelkel, A. A. Fowler, and R. Natarajan, "Vitamin C Prevents Sepsis Induced Organ Injury By Attenuating Neutrophil Extracellular Trap Formation", Am J Respir Crit Care Med, vol. 187: Am Thoracic Soc, pp. A3841, 2013. Abstract
n/a
Mohamed, A. A., and B. Venkatesh, "Voltage stability constrained line-wise optimal power flow", IET Generation, Transmission & Distribution, vol. 13, no. 8: IET Digital Library, pp. 1332–1338, 2019. Abstract
n/a
Howard, J., K. I. Ataga, R. C. Brown, M. Achebe, V. Nduba, A. El-Beshlawy, H. Hassab, I. Agodoa, M. Tonda, S. Gray, et al., "Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.", The Lancet. Haematology, vol. 8, issue 5, pp. e323-e333, 2021. Abstract

BACKGROUND: For decades, patients with sickle cell disease have had only a limited number of therapies available. In 2019, voxelotor (1500 mg), an oral once-daily sickle haemoglobin polymerisation inhibitor, was approved in the USA for the treatment of sickle cell disease in patients aged 12 years and older on the basis of HOPE trial data. To further describe the applicability of voxelotor as a treatment for this chronic illness, we report the long-term efficacy and safety of this drug at 72 weeks of treatment; the conclusion of the placebo-controlled HOPE trial.

METHODS: HOPE is an international, randomised, double-blind, placebo-controlled, phase 3 trial done at 60 clinical sites in Canada, Egypt, France, Italy, Jamaica, Kenya, Lebanon, Netherlands, Oman, Turkey, the USA, and the UK. Patients (aged 12-65 years) with confirmed sickle cell disease, a haemoglobin concentration of 5·5-10·5 g/dL at enrolment, and who had between one and ten vaso-occlusive crisis events in the previous 12 months were enrolled. Patients receiving regularly scheduled transfusion therapy, who had received a transfusion in the previous 60 days, or who had been admitted to hospital for a vaso-occlusive crisis in the previous 14 days were excluded. Patients were randomly assigned (1:1:1) to receive either once-daily oral voxelotor 1500 mg, voxelotor 900 mg, or placebo for 72 weeks. Randomisation was done centrally by use of an interactive web response system, stratified by baseline hydroxyurea use (yes vs no), age group (adolescents [12 to <18 years] vs adults [18 to 65 years]), and geographic region (North America vs Europe vs other). The primary endpoint (already reported) was the proportion of patients who achieved a haemoglobin response at week 24. In this final analysis, we report prespecified long-term efficacy assessments by intention to treat, including changes in haemoglobin concentrations from baseline to week 72, changes in the concentration of haemolysis markers (absolute and percentage reticulocytes, indirect bilirubin concentrations, and lactate dehydrogenase concentrations) from baseline to week 72, the annualised incidence of vaso-occlusive crises, and patient functioning, as assessed with the Clinical Global Impression of Change (CGI-C) scale. Safety was assessed in patients who received at least one dose of treatment (modified intention-to-treat population). This trial is registered with ClinicalTrials.gov, NCT03036813.

FINDINGS: Between Dec 5, 2016, and May 3, 2018, 449 patients were screened, of whom 274 were randomly assigned to the voxelotor 1500 mg group (n=90), the voxelotor 900 mg group (n=92), or the placebo group (n=92). At week 72, the adjusted mean change in haemoglobin concentration from baseline was 1·0 g/dL (95% CI 0·7 to -1·3) in the voxelotor 1500 mg group, 0·5 g/dL (0·3 to -0·8) in the voxelotor 900 mg group, and 0·0 g/dL (-0·3 to 0·3) in the placebo group, with a significant difference observed between the voxelotor 1500 mg group and the placebo group (p<0·0001), and between the voxelotor 900 mg group and the placebo group (p=0·014). Significant improvements in markers of haemolysis, as assessed by the difference in adjusted mean percentage change from baseline at week 72 versus placebo, were observed in the voxelotor 1500 mg group in indirect bilirubin concentrations (-26·6% [95% CI -40·2 to -12·9]) and percentage of reticulocytes (-18·6% [-33·9 to -3·3]). The proportion of patients in the voxelotor 1500 mg group who were rated as "moderately improved" or "very much improved" at week 72 with the CGI-C was significantly greater than in the placebo group (39 [74%] of 53 vs 24 [47%] of 51; p=0·0057). Serious adverse events unrelated to sickle cell disease were reported in 25 (28%) of 88 patients in the voxelotor 1500 mg group, 20 (22%) of 92 patients in the voxelotor 900 mg group, and 23 (25%) of 91 patients in the placebo group. Grade 3 or 4 adverse events were infrequent (ie, occurred in <10% of patients); anaemia occurred in five or more patients (two [2%] patients in the voxelotor 1500 mg group, seven [8%] patients in the voxelotor 900 mg group, and three [3%] patients in the placebo group). Of all 274 patients, six (2%) deaths occurred during the study (two deaths in each treatment group), all of which were judged as unrelated to treatment.

INTERPRETATION: Voxelotor 1500 mg resulted in rapid and durable improvements in haemoglobin concentrations maintained over 72 weeks and has potential to address the substantial morbidity associated with haemolytic anaemia in sickle cell disease.

FUNDING: Global Blood Therapeutics.

Awad, Z., S. Viti, M. P. Collings, and D. A. Williams, "Warm cores around regions of low-mass star formation", Monthly Notices of the Royal Astronomical Society, vol. 407, no. 4: Oxford University Press, pp. 2511–2518, 2010. Abstract
n/a
Hassan, M., S. Mansour, S. Voigt, and M. Gadallah, "When Syria was in Egypt's land: Egyptians cooperate with Syrians, but less each other", Public Choice, vol. 191, pp. 337-362, 2022.
Hassan, M., S. Mansour, S. Voigt, and M. Gadallah, "When Syria was in Egypt’s Land - Egyptians Cooperate with Syrians, but less with each other", Public Choice, 2020.
Hassan, M., S. Mansour, S. Voigt, and M. Gadalla, "When Syria was in Egypt’s Land: Egyptians Cooperate with Syrians, but less with each other", Public Choice, vol. 191, issue 3-4, pp. 337-362, 2022.
Elbendary, A., M. Valdebran, A. A. Gad, and D. M. Elston, "When to suspect tinea; a histopathologic study of 103 cases of PAS-positive tinea.", Journal of cutaneous pathology, vol. 43, issue 10, pp. 852-7, 2016 Oct. Abstract

BACKGROUND: The histopathologic features of tinea vary widely and its diagnosis could be easily missed if the index of suspicion is not high. We aimed in this study to detect histopathologic features that could be a clue for diagnosis

METHODS: We retrospectively reviewed 103 cases of tinea, confirmed by Periodic acid-Schiff (PAS) staining. For each case, gender, biopsy site, and pre-biopsy suspicion were recorded. The presence or absence of 17 microscopic features was noted.

RESULTS: Concordance between pre-biopsy and histopathologic diagnosis was noted in 57.28% of cases, suggesting that the diagnosis is often not suspected clinically. Among the histopathologic features studied, a compact stratum corneum (either uniform or forming a layer beneath a basket weave stratum corneum), parakeratosis, mild spongiosis and neutrophils in the stratum corneum and within the blood vessels were the most frequent features noted.

CONCLUSION: This study suggests histopathologic clues that should prompt the pathologist to order a PAS stain, especially when diagnosis is not suspected clinically.

Elbendary, A., M. Valdebran, A. A. Gad, and D. M. Elston, "When to suspect tinea; a histopathologic study of 103 cases of PAS-positive tinea.", Journal of cutaneous pathology, vol. 43, issue 10, pp. 852-7, 2016 Oct. Abstract

BACKGROUND: The histopathologic features of tinea vary widely and its diagnosis could be easily missed if the index of suspicion is not high. We aimed in this study to detect histopathologic features that could be a clue for diagnosis

METHODS: We retrospectively reviewed 103 cases of tinea, confirmed by Periodic acid-Schiff (PAS) staining. For each case, gender, biopsy site, and pre-biopsy suspicion were recorded. The presence or absence of 17 microscopic features was noted.

RESULTS: Concordance between pre-biopsy and histopathologic diagnosis was noted in 57.28% of cases, suggesting that the diagnosis is often not suspected clinically. Among the histopathologic features studied, a compact stratum corneum (either uniform or forming a layer beneath a basket weave stratum corneum), parakeratosis, mild spongiosis and neutrophils in the stratum corneum and within the blood vessels were the most frequent features noted.

CONCLUSION: This study suggests histopathologic clues that should prompt the pathologist to order a PAS stain, especially when diagnosis is not suspected clinically.

Carson, M., J. K. Keppler, G. Brackman, D. Dawood, M. Vandrovcova, K. Fawzy El-Sayed, T. Coenye, K. Schwarz, S. A. Clarke, and A. G. Skirtach, "Whey protein complexes with green tea polyphenols: antimicrobial, osteoblast-stimulatory, and antioxidant activities", Cells Tissues Organs, vol. 206, issue 1-2: Karger Publishers, pp. 106-118, 2018. Abstract
n/a
Carson, M., J. K. Keppler, G. Brackman, D. Dawood, M. Vandrovcova, K. Fawzy El-Sayed, T. Coenye, K. Schwarz, S. A. Clarke, and A. G. Skirtach, "Whey protein complexes with green tea polyphenols: antimicrobial, osteoblast-stimulatory, and antioxidant activities", Cells Tissues Organs, vol. 206, issue 1-2: Karger Publishers, pp. 106-118, 2018. Abstract
n/a
Daga, A., A. J. Majmundar, D. A. Braun, H. Y. Gee, J. A. Lawson, S. Shril, T. Jobst-Schwan, A. Vivante, D. Schapiro, W. Tan, et al., "Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis.", Kidney international, vol. 93, issue 1, pp. 204-213, 2018 Jan. Abstract

The incidence of nephrolithiasis continues to rise. Previously, we showed that a monogenic cause could be detected in 11.4% of individuals with adult-onset nephrolithiasis or nephrocalcinosis and in 16.7-20.8% of individuals with onset before 18 years of age, using gene panel sequencing of 30 genes known to cause nephrolithiasis/nephrocalcinosis. To overcome the limitations of panel sequencing, we utilized whole exome sequencing in 51 families, who presented before age 25 years with at least one renal stone or with a renal ultrasound finding of nephrocalcinosis to identify the underlying molecular genetic cause of disease. In 15 of 51 families, we detected a monogenic causative mutation by whole exome sequencing. A mutation in seven recessive genes (AGXT, ATP6V1B1, CLDN16, CLDN19, GRHPR, SLC3A1, SLC12A1), in one dominant gene (SLC9A3R1), and in one gene (SLC34A1) with both recessive and dominant inheritance was detected. Seven of the 19 different mutations were not previously described as disease-causing. In one family, a causative mutation in one of 117 genes that may represent phenocopies of nephrolithiasis-causing genes was detected. In nine of 15 families, the genetic diagnosis may have specific implications for stone management and prevention. Several factors that correlated with the higher detection rate in our cohort were younger age at onset of nephrolithiasis/nephrocalcinosis, presence of multiple affected members in a family, and presence of consanguinity. Thus, we established whole exome sequencing as an efficient approach toward a molecular genetic diagnosis in individuals with nephrolithiasis/nephrocalcinosis who manifest before age 25 years.

Warejko, J. K., W. Tan, A. Daga, D. Schapiro, J. A. Lawson, S. Shril, S. Lovric, S. Ashraf, J. Rao, T. Hermle, et al., "Whole Exome Sequencing of Patients with Steroid-Resistant Nephrotic Syndrome.", Clinical journal of the American Society of Nephrology : CJASN, vol. 13, issue 1, pp. 53-62, 2018 Jan 06. Abstract

BACKGROUND AND OBJECTIVES: Steroid-resistant nephrotic syndrome overwhelmingly progresses to ESRD. More than 30 monogenic genes have been identified to cause steroid-resistant nephrotic syndrome. We previously detected causative mutations using targeted panel sequencing in 30% of patients with steroid-resistant nephrotic syndrome. Panel sequencing has a number of limitations when compared with whole exome sequencing. We employed whole exome sequencing to detect monogenic causes of steroid-resistant nephrotic syndrome in an international cohort of 300 families.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Three hundred thirty-five individuals with steroid-resistant nephrotic syndrome from 300 families were recruited from April of 1998 to June of 2016. Age of onset was restricted to <25 years of age. Exome data were evaluated for 33 known monogenic steroid-resistant nephrotic syndrome genes.

RESULTS: In 74 of 300 families (25%), we identified a causative mutation in one of 20 genes known to cause steroid-resistant nephrotic syndrome. In 11 families (3.7%), we detected a mutation in a gene that causes a phenocopy of steroid-resistant nephrotic syndrome. This is consistent with our previously published identification of mutations using a panel approach. We detected a causative mutation in a known steroid-resistant nephrotic syndrome gene in 38% of consanguineous families and in 13% of nonconsanguineous families, and 48% of children with congenital nephrotic syndrome. A total of 68 different mutations were detected in 20 of 33 steroid-resistant nephrotic syndrome genes. Fifteen of these mutations were novel.,,, andwere the most common genes in which we detected a mutation. In another 28% of families, we detected mutations in one or more candidate genes for steroid-resistant nephrotic syndrome.

CONCLUSIONS: Whole exome sequencing is a sensitive approach toward diagnosis of monogenic causes of steroid-resistant nephrotic syndrome. A molecular genetic diagnosis of steroid-resistant nephrotic syndrome may have important consequences for the management of treatment and kidney transplantation in steroid-resistant nephrotic syndrome.

van der Ven, A. T., D. M. Connaughton, H. Ityel, N. Mann, M. Nakayama, J. Chen, A. Vivante, D. - Y. Hwang, J. Schulz, D. A. Braun, et al., "Whole-Exome Sequencing Identifies Causative Mutations in Families with Congenital Anomalies of the Kidney and Urinary Tract.", Journal of the American Society of Nephrology : JASN, vol. 29, issue 9, pp. 2348-2361, 2018 Sep. Abstract

BACKGROUND: Congenital anomalies of the kidney and urinary tract (CAKUT) are the most prevalent cause of kidney disease in the first three decades of life. Previous gene panel studies showed monogenic causation in up to 12% of patients with CAKUT.

METHODS: We applied whole-exome sequencing to analyze the genotypes of individuals from 232 families with CAKUT, evaluating for mutations in single genes known to cause human CAKUT and genes known to cause CAKUT in mice. In consanguineous or multiplex families, we additionally performed a search for novel monogenic causes of CAKUT.

RESULTS: In 29 families (13%), we detected a causative mutation in a known gene for isolated or syndromic CAKUT that sufficiently explained the patient's CAKUT phenotype. In three families (1%), we detected a mutation in a gene reported to cause a phenocopy of CAKUT. In 15 of 155 families with isolated CAKUT, we detected deleterious mutations in syndromic CAKUT genes. Our additional search for novel monogenic causes of CAKUT in consanguineous and multiplex families revealed a potential single, novel monogenic CAKUT gene in 19 of 232 families (8%).

CONCLUSIONS: We identified monogenic mutations in a known human CAKUT gene or CAKUT phenocopy gene as the cause of disease in 14% of the CAKUT families in this study. Whole-exome sequencing provides an etiologic diagnosis in a high fraction of patients with CAKUT and will provide a new basis for the mechanistic understanding of CAKUT.

Abdel-Aziz, H., W. Wadie, D. M. Abdallah, B. Vinson, O. Kelber, D. Weiser, and M. T. Khayyal, "Wirkung von STW 5 in einem experimentellen Kolitis-Modell", Zeitschrift für Gastroenterologie, vol. 46, no. 09, pp. P362, 2008. Abstract
n/a
Abdel-Aziz, H., W. Wadie, D. M. Abdallah, B. Vinson, O. Kelber, D. Weiser, and M. T. Khayyal, "Wirkung von STW 5 in einem experimentellen Kolitis-Modell", Zeitschrift für Gastroenterologie, vol. 46, issue 09, pp. P362, Submitted. Abstract
n/a
Ahmed, A. A., A. A. Mohamed, I. A. Guled, H. M. Elamin, A. H. Abou-Zeid, J. Loko Roka, R. Van den Bergh, S. Au, E. De Plecker, R. Zachariah, et al., Womens/Reproductive Health:[32], , Submitted. Abstract
n/a
Umar, M., A. G. Khan, Z. Abbas, S. Arora, N. Asifabbas, A. Elewaut, G. Esmat, G. Foster, M. Fried, K. - L. Goh, et al., "World Gastroenterology Organisation global guidelines: diagnosis, management and prevention of hepatitis C April 2013.", Journal of clinical gastroenterology, vol. 48, issue 3, pp. 204-17, 2014 Mar. Abstract
n/a
Tilz, R. R., V. Schmidt, H. Pürerfellner, P. Maury, K. R. J. ulian Chun, M. Martinek, C. Sohns, B. Schmidt, F. Mandel, E. Gandjbakhch, et al., A worldwide survey on incidence, management, and prognosis of oesophageal fistula formation following atrial fibrillation catheter ablation: the POTTER-AF study, , vol. 44, issue 27, pp. 2458 - 2469, 2023/07/14. AbstractWebsite

Oesophageal fistula represents a rare but dreadful complication of atrial fibrillation catheter ablation. Data on its incidence, management, and outcome are sparse.This international multicentre registry investigates the characteristics of oesophageal fistulae after treatment of atrial fibrillation by catheter ablation. A total of 553 729 catheter ablation procedures (radiofrequency: 62.9%, cryoballoon: 36.2%, other modalities: 0.9%) were performed, at 214 centres in 35 countries. In 78 centres 138 patients [0.025%, radiofrequency: 0.038%, cryoballoon: 0.0015% (P < 0.0001)] were diagnosed with an oesophageal fistula. Peri-procedural data were available for 118 patients (85.5%). Following catheter ablation, the median time to symptoms and the median time to diagnosis were 18 (7.75, 25; range: 0–60) days and 21 (15, 29.5; range: 2–63) days, respectively. The median time from symptom onset to oesophageal fistula diagnosis was 3 (1, 9; range: 0–42) days. The most common initial symptom was fever (59.3%). The diagnosis was established by chest computed tomography in 80.2% of patients. Oesophageal surgery was performed in 47.4% and direct endoscopic treatment in 19.8% and conservative treatment in 32.8% of patients. The overall mortality was 65.8%. Mortality following surgical (51.9%) or endoscopic treatment (56.5%) was significantly lower as compared to conservative management (89.5%) [odds ratio 7.463 (2.414, 23.072) P < 0.001].Oesophageal fistula after catheter ablation of atrial fibrillation is rare and occurs mostly with the use of radiofrequency energy rather than cryoenergy. Mortality without surgical or endoscopic intervention is exceedingly high.

Vannozzi, A., I. Hmmam, J. Holl, J. Bogs, I. Dry, G. Barcaccia, and M. Lucchin, "WRKY transcription factors and regulation of the stilbene biosynthetic pathway in grapevine: new insights and perspectives", Acta Hort, vol. 1188, pp. 1-8, 2017.
Tourism